French Medtech Reimbursement - How Added Value And Clinical Benefit Sway Decisions
This article is powered by Medtech Insight
Executive Summary
In France, many medical devices require value assessments prior to securing market access, a process that manufacturers may find complex. Hubert Galmiche, head of medical device assessment at the French National Authority for Health (HAS) explains what the outcomes of these appraisals mean for companies.
You may also be interested in...
France Latest Country To Introduce Digital Medtech Reimbursement Fast-Track
France has introduced a fast-track market access pathway for certain digital health products, adding to similar schemes in neighboring EU countries Germany and Belgium. But how does the new reimbursement program work, and which products are eligible for coverage?
Germany’s Digital Health Fast-Track Scheme: What Manufacturers Need To Know
Understanding the German reimbursement system is crucial for any medtech firm eyeing the European market, and healthtech innovators in particular may benefit from its fast-track digital health app scheme. But how does the scheme work, and who can apply?
French Medtech System ‘Too Rigorous’ For Innovation To Flourish, Argues Healthtech Expert
David Caumartin is well versed in the both the benefits and drawbacks of being a France-based medtech innovator, having spent almost three decades in the local industry. The VP of France Biotech spoke to Medtech Insight about the new opportunities there to be seized, and the pitfalls to avoid.